POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (latest WHO data):   India 18,327    Brazil 75,102    Russia 11,024    The United Kingdom 6,573    France 24,739    Spain 2,676    Italy 22,845    Turkey 11,322    Germany 10,580    Columbia 3,565    Argentina 11,767    Mexico 7,521    Poland 15,831    Iran 8,367    South Africa 1,404    Ukraine 10,155    Indonesia 6,971    Peru 4,878    Czechia 14,714    The Netherlands 4,161    Canada 2,832    Chile 5,331    Romania 4,271    Iraq 5,127    Sweden 4,864    Philippines 3,037    Pakistan 1,579    Serbia 3,866    Austria 2,691    Hungary 6,369    Japan 1,164    Jordan 4,584    United Arab Emirates 3,072    Lebanon 3,202    Slovakia 2,423    Malaysia 2,154    Belarus 1,174    Ecuador 1,335    Bulgaria 2,198    Palestine 1,826    Greece 2,217    Kuwait 1,613    Slovenia 1,019    Moldova 1,800    Paraguay 1,439    Estonia 1,534    China 21    Singapore 9    New Zealand 9    Australia 18    South Korea 417   

U.S. volunteer receives first shot of experimental coronavirus vaccine

Christian Fernsby |
U.S. researchers gave the first shot to the first person in a test of an experimental coronavirus vaccine yesterday.

Article continues below



Topics: U.S.    CORONAVIRUS    VACCINE   

With a careful jab in a healthy volunteer’s arm, scientists at the Kaiser Permanente Washington Research Institute in Seattle begin an anxiously awaited first stage study of a potential COVID-19 vaccine developed in record tim.

“We’re team coronavirus now,” Kaiser Permanente study leader Dr. Lisa Jackson said on the eve of the experiment. “Everyone wants to do what they can in this emergency.”

The Associated Press observed as the study’s first participant, an operations manager at a small tech company, received the injection inside an exam room. Several others were next in line for a test that will ultimately give 45 volunteers two doses, a month apart.

“We all feel so helpless. This is an amazing opportunity for me to do something,” said Jennifer Haller, 43, of Seattle. She’s the mother of two teenagers and “they think it’s cool” that she’s taking part in the study.

Monday’s milestone marked just the beginning of a series of studies in people needed to prove whether the shots are safe and could work. Even if the research goes well, a vaccine wouldn’t be available for widespread use for 12 to 18 months, said Dr. Anthony Fauci of the U.S. National Institutes of Health. That’s still important if the virus becomes a long-term threat.

This vaccine candidate, code-named mRNA-1273, was developed by the NIH and Massachusetts-based biotechnology company Moderna Inc. There’s no chance participants could get infected from the shots because they don’t contain the coronavirus itself.


What to read next

DNA-based vaccine guards against Zika in monkey study
Zika vaccine works in early human trial
3-in-1 vaccine against traveler's diarrhea